Baltimore-based clinical research firm signs $2.2 mil. product development contract and royalty agreement with "a leading generic U.S. pharmaceutical manufacturer." Agreement calls for PharmaKinetics to provide for management, design and execution of all regulatory and clinical research required to complete an ANDA for "a generic drug." Firm says "substantially all" services are to be performed over the next 18 months.
You may also be interested in...
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.